EMPOWERING YOU TO TAKE ACTION

Transforming Cardiometabolic Care

Cardiometabolic disease is the #1 public health challenge worldwide. Yet, most people living with cardiometabolic disease do not get evidence-based care. Together, we can change this.

CardioMetabolic Health Foundation shield
  • #1 Cause of global mortality & morbidity
  • >75% Of patients unnecessarily remain at higher risk
  • 4 Getting to goal on 4 metrics (Adiposity, Blood Pressure, Cholesterol and Diabetes) can substantially reduce risk

THE PROBLEM

The Evidence Exists. The Care Doesn’t.

Cardiometabolic diseases — encompassing cardiovascular disease, diabetes, obesity, hypertension, dyslipidaemia, and metabolic renal/hepatic damage — represent the foremost threat to global public health.

While modern medicine has unlocked transformative therapies (including GLP-1 receptor agonists, SGLT2 inhibitors, and PCSK9 inhibitors), a devastating implementation gap persists. Irrefutable, concrete clinical trial evidence exists, yet the majority of patients do not achieve guideline-directed standards of care.

Even highly educated, proactive individuals struggle to navigate and protect their cardiometabolic health in an evidence-based manner.

If we can fix this, we will touch the lives of millions of people, and save billions in healthcare spend.

OUR MISSION

“To organise the cardiometabolic evidence base and make it universally accessible and actionable, thereby improving the quality and quantity of life for people at risk of cardiometabolic illnesses worldwide.”

THE FOUNDATIONAL FRAMEWORK

The ABCD & Me Framework

Cardio-kidney-liver protection requires holistic, interconnected evaluation rather than treating isolated risk markers. We organise preventative health around the comprehensive ABCD & Me clinical paradigm.

  • A

    Adiposity

    Optimising body composition, visceral adiposity, and weight-related metabolic health through nutritional and therapeutic pathways.

  • B

    Blood Pressure

    Strict systolic and diastolic regulation to prevent endothelial dysfunction, arterial stiffness, heart failure, and renal microvascular decline.

  • C

    Cholesterol & Lipids

    Atherogenic particle clearance (ApoB, LDL-C, Non-HDL, Triglycerides) and plaque stabilisation using evidence-backed lipid management.

  • D

    Diabetes & Pre-Diabetes

    Early glycaemic intervention, insulin sensitivity optimisation, and glycaemic variability mitigation to arrest organ damage.

  • & Me

    Personalised care pathways including addressing sex-differentiated risks: bone health, cardiovascular risk transition in menopause for women; androgenic & vascular health for men.

ADDRESSING THE GAPS IN CURRENT HEALTHCARE DELIVERY

Bridging Gaps in Care

Current medical ecosystems were structured around reactive acute illness rather than proactive cardiometabolic prevention. Our aim is to take a system-wide approach across all three major healthcare stakeholder tiers.

01

Patients

CURRENT GAPS & FAILURE POINTS

  • No integrated dashboard to view multi-organ long-term health
  • Inability to link personal wellness data (steps, calories) to clinical outcomes
  • Proliferation of social media misinformation and untrusted medical sources
  • ‘Short-term fix’ mindset instead of lifelong organ preservation

CARMEF STRATEGIC SOLUTION

Empower individuals to actively participate in their own care through clear health tracking, accessible education, and shared decision-making.

02

Healthcare Professionals (HCPs)

CURRENT GAPS & FAILURE POINTS

  • Fragmented clinical guidelines addressing single risk factors in isolation
  • Lack of unified coaching toolkits for multi-morbidity consultations
  • No clear algorithmic guidance on ‘next best action’ across complex cases
  • Severe clinical time constraints during routine appointments

CARMEF STRATEGIC SOLUTION

Equip healthcare professionals with unified clinical guidance, practical decision-support tools, and cross-disciplinary education to deliver proactive, organ-protective care.

03

Health Systems & Payers

CURRENT GAPS & FAILURE POINTS

  • Acute illness infrastructure poorly suited for long-term chronic management
  • Misallocation of costly specialist appointments to late-stage disease
  • Suboptimal attainment of population health quality metrics
  • High avoidable expenditures on late cardiovascular and renal failure admissions

CARMEF STRATEGIC SOLUTION

Enable health systems and payers to transition towards sustainable prevention through economic value models, scalable risk screening, community partnerships, and streamlined care pathways.

LEADERSHIP & BOARD OF TRUSTEES

Leadership

The CardioMetabolic Health Foundation is a new charity, founded in 2026 by Dr. Jyothis George. It is governed by a board of trustees: experienced senior physician-scientists and healthcare leaders with expertise spanning academic research, hospital cardiology leadership and frontline primary care practice. Their collective backgrounds drive the charity’s mission to bridge the gap between breakthrough clinical trials and routine preventive care.

A global scientific advisory board is being put together, with expertise from several domains: cardiometabolic experts, people living with cardiometabolic disease, healthcare system leaders and technology experts.

If our mission resonates with you, please join us!

Partner With Us

Please don’t include personal medical details. We’ll use your details only to reply — see our privacy notice.

Or email us at collaborate@cardiometabolic.foundation